FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310103277> ?p ?o ?g. }

• W4310103277 endingPage "9349" @default.
• W4310103277 startingPage "9347" @default.
• W4310103277 abstract "Introduction: Splenic Marginal Zone Lymphoma (SMZL) is an uncommon subtype of non-Hodgkin Lymphoma, therefore, the data concerning the diagnosis, prognosis and treatment are scare and mostly based on a limited number of retrospective series. In 2014, GELTAMO group launched a guidelines for practical management of SMZL to be used in the everyday practice in this nation-wide network of collaborative hospitals. (GEL-LZME-2014-14). These Guidelines proposed/suggested different treatment strategies according to the HPLLs/ABC score (Montalban et al, 2012). Therapeutic recommendations were observation (W&W) in group A, rituximab in group B and rituximab in combination with chemotherapy (R-Chemotherapy) in group C. The primary endpoint was to analyze compliance with the guidelines and to evaluate the outcome according to the HPLLs/ABC-adapted therapeutic strategy in the real life. Methods: Observational multicenter study of patients with diagnostic of SMZL between 2014 and 2019 included prospectively and consecutively in the RELINF registry by Spanish GELTAMO centers. Clinical data at diagnosis, HPLLs/ABC prognostic index, treatment, response and follow up were obtained from the medical records and entered into a database. Lymphoma Specific Survival (LSS) and response rates according to treatment received were assessed in this study. Composite event free survival (CEFS) defined as death, histological transformation (HT), recurrence/progression under treatment, and need for treatment under observation, was also analyzed. HT was considered as a time-dependent event. Results: A total of 181 patients (84M/97F; median age 71 years) from 22 centers were included. The main initial characteristics of the patients are shown in Table 1. Splenectomy was performed in 17 cases (9%). 57% of the patients followed the recommendation of the GELTAMO Guidelines. 13 cases were excluded for response and survival analyses (i.e., 3 with HT at diagnosis, 5 treated for hepatitis C virus and 5 managed with palliative care). At diagnosis 77 patients (45%) received some therapy while 96 (55%) remained on W&W (Table 1). The overall response rate was higher in the R-Chemotherapy arm and in the Rituximab arm compared to splenectomy (p<0.001), with no significant differences between Rituximab and R-Chemotherapy. With a median follow up of 41.2 months, the 5-year overall survival (OS) of the whole series was 77%, and the 5-year LSS of 93%, with 32 patients (18%) dying, but only 13 (40%) due to the lymphoma or its treatment. 5-year LSS was 98% and 87% for score A and B, respectively (p=0.048), but unexpectedly, there were no deaths among the 9 patients of score C (5-year LSS: 100%). There were no differences in the 5-year LSS according to the treatment received in the overall series (p=0.68) (Figure 1), nor when scores A and B were analyzed separately. The 5-year CEFS in the overall series was 46%. Analyzing the composed event according to score, there were significant differences in terms of the 5-year CEFS between scores A and B (p=0.044). When comparing LSS and progression-free survival (PFS) in patients treated with Rituximab or R-Chemotherapy at diagnosis or after the W&W period, there were no significant differences between the two groups. Patients on score C had a higher risk of HT than the remaining groups (HT at 5 years: 1.3%, 6.6% and 36% for scores A, B and C, respectively; p<0.001). HT was associated with significantly lower OS (Cox-time dependent: HR 7.816, 95% CI 3.179-19.217; p<0.001). Conclusions: Herein we describe the everyday practice for diagnosis, stratification, and treatment of SMZL in Spain. Overall, 57% of the patients were managed according to the Guidelines. Our data support that Rituximab is the best treatment, when needed. Patients with score A who do not need immediate treatment after diagnosis and are followed with W&W policy have a very good outcome. In patients with scores A and B who were observed after initial diagnosis, the response to Rituximab at the time of need of therapy was not hampered when compared to patients receiving Rituximab immediately after diagnosis. HT is associated with reduced survival. The low number of cases in score C prevents us from drawing conclusions in this group at this time. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310103277 created "2022-11-30" @default.
• W4310103277 creator A5004725639 @default.
• W4310103277 creator A5006538688 @default.
• W4310103277 creator A5007117385 @default.
• W4310103277 creator A5010206363 @default.
• W4310103277 creator A5010733763 @default.
• W4310103277 creator A5012630795 @default.
• W4310103277 creator A5014603402 @default.
• W4310103277 creator A5015493927 @default.
• W4310103277 creator A5015753706 @default.
• W4310103277 creator A5016510706 @default.
• W4310103277 creator A5021355219 @default.
• W4310103277 creator A5025303371 @default.
• W4310103277 creator A5034861019 @default.
• W4310103277 creator A5035788596 @default.
• W4310103277 creator A5044921844 @default.
• W4310103277 creator A5061783632 @default.
• W4310103277 creator A5065232101 @default.
• W4310103277 creator A5069388075 @default.
• W4310103277 creator A5074962085 @default.
• W4310103277 creator A5076514135 @default.
• W4310103277 creator A5077730260 @default.
• W4310103277 creator A5079586596 @default.
• W4310103277 creator A5083191976 @default.
• W4310103277 date "2022-11-15" @default.
• W4310103277 modified "2023-09-29" @default.
• W4310103277 title "Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group" @default.
• W4310103277 doi "https://doi.org/10.1182/blood-2022-160073" @default.
• W4310103277 hasPublicationYear "2022" @default.
• W4310103277 type Work @default.
• W4310103277 citedByCount "0" @default.
• W4310103277 crossrefType "journal-article" @default.
• W4310103277 hasAuthorship W4310103277A5004725639 @default.
• W4310103277 hasAuthorship W4310103277A5006538688 @default.
• W4310103277 hasAuthorship W4310103277A5007117385 @default.
• W4310103277 hasAuthorship W4310103277A5010206363 @default.
• W4310103277 hasAuthorship W4310103277A5010733763 @default.
• W4310103277 hasAuthorship W4310103277A5012630795 @default.
• W4310103277 hasAuthorship W4310103277A5014603402 @default.
• W4310103277 hasAuthorship W4310103277A5015493927 @default.
• W4310103277 hasAuthorship W4310103277A5015753706 @default.
• W4310103277 hasAuthorship W4310103277A5016510706 @default.
• W4310103277 hasAuthorship W4310103277A5021355219 @default.
• W4310103277 hasAuthorship W4310103277A5025303371 @default.
• W4310103277 hasAuthorship W4310103277A5034861019 @default.
• W4310103277 hasAuthorship W4310103277A5035788596 @default.
• W4310103277 hasAuthorship W4310103277A5044921844 @default.
• W4310103277 hasAuthorship W4310103277A5061783632 @default.
• W4310103277 hasAuthorship W4310103277A5065232101 @default.
• W4310103277 hasAuthorship W4310103277A5069388075 @default.
• W4310103277 hasAuthorship W4310103277A5074962085 @default.
• W4310103277 hasAuthorship W4310103277A5076514135 @default.
• W4310103277 hasAuthorship W4310103277A5077730260 @default.
• W4310103277 hasAuthorship W4310103277A5079586596 @default.
• W4310103277 hasAuthorship W4310103277A5083191976 @default.
• W4310103277 hasBestOaLocation W43101032771 @default.
• W4310103277 hasConcept C126322002 @default.
• W4310103277 hasConcept C143998085 @default.
• W4310103277 hasConcept C2776309230 @default.
• W4310103277 hasConcept C2779338263 @default.
• W4310103277 hasConcept C2779380147 @default.
• W4310103277 hasConcept C2780653079 @default.
• W4310103277 hasConcept C2780931953 @default.
• W4310103277 hasConcept C71924100 @default.
• W4310103277 hasConceptScore W4310103277C126322002 @default.
• W4310103277 hasConceptScore W4310103277C143998085 @default.
• W4310103277 hasConceptScore W4310103277C2776309230 @default.
• W4310103277 hasConceptScore W4310103277C2779338263 @default.
• W4310103277 hasConceptScore W4310103277C2779380147 @default.
• W4310103277 hasConceptScore W4310103277C2780653079 @default.
• W4310103277 hasConceptScore W4310103277C2780931953 @default.
• W4310103277 hasConceptScore W4310103277C71924100 @default.
• W4310103277 hasIssue "Supplement 1" @default.
• W4310103277 hasLocation W43101032771 @default.
• W4310103277 hasOpenAccess W4310103277 @default.
• W4310103277 hasPrimaryLocation W43101032771 @default.
• W4310103277 hasRelatedWork W2105813567 @default.
• W4310103277 hasRelatedWork W2143803333 @default.
• W4310103277 hasRelatedWork W2391661238 @default.
• W4310103277 hasRelatedWork W2396335856 @default.
• W4310103277 hasRelatedWork W2414762484 @default.
• W4310103277 hasRelatedWork W2805808559 @default.
• W4310103277 hasRelatedWork W2889021991 @default.
• W4310103277 hasRelatedWork W4280524017 @default.
• W4310103277 hasRelatedWork W4382536683 @default.
• W4310103277 hasRelatedWork W4382585346 @default.
• W4310103277 hasVolume "140" @default.
• W4310103277 isParatext "false" @default.
• W4310103277 isRetracted "false" @default.
• W4310103277 workType "article" @default.